Clinical Trial Update: Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial investigating azacitidine combined with pembrolizumab for high-risk myelodysplastic syndrome (IPSS intermediate-1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1 | Phase 2 | Status: UNKNOWN | Results posted: 2021-10-01